A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

Recruiting now · Phase 1

Conditions studied: Metastatic Castration-resistant Prostate Cancer

In brief

The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.

Key facts

Study ID

NCT06067841

Run by

Bristol-Myers Squibb

People needed

140

Starts

2023-10-18

Expected to finish

2031-07-27

Last updated by the study team

2026-02-04

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Participant must have histologically or cytologically confirmed adenocarcinoma of the prostate.
• Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.
• Participant must have prostate specific antigen (PSA) of ≥ 2 ng/mL at Screening
• Participant must have progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC)

You may not qualify if…

• Participant must not have history of brain metastases.
• Participant must not have impaired cardiac function or clinically significant cardiac disease.
• Participant must not have any significant medical condition, including active or uncontrolled infection, psychiatric illness, or the presence of laboratory abnormalities, which places the participant at unacceptable risk or prevent participation in the study based on Investigator assessment.
• Other protocol-defined inclusion/exclusion criteria apply

Where it is running

• Fred Hutchinson Cancer Center — Seattle, Washington, United States (enrolling)
• Florida Cancer Specialists Sarasota Drug Development Unit — Sarasota, Florida, United States (enrolling)
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
• Memorial Sloan Kettering Cancer Center — New York, New York, United States (enrolling)
• Duke Cancer Institute — Durham, North Carolina, United States (enrolling)
• Stanford Cancer Center — Palo Alto, California, United States (enrolling)
• NEXT Oncology — San Antonio, Texas, United States (enrolling)
• Local Institution - 0006 — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.